Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9449475 | 1.00 | PTPN1 (0.50) | PTPN1MDM4TP53CASP3KMT2A | |
| SCHEMBL29531966 | 0.95 | PTPN1 (0.53) | PTPN1MDM4TP53 | |
| SCHEMBL30261676 | 0.95 | PTPN1 (0.53) | PTPN1MDM4TP53 | |
| Hydrochloric Acid SCHEMBL29601405 | 0.94 | PTPN1 (0.53) | PTPN1MDM4TP53 | |
| SCHEMBL12228627 | 0.92 | PTPN1 (0.49) | PTPN1CASP3KMT2AUSP2 | |
| Hydrochloric Acid SCHEMBL30233326 | 0.91 | PTPN1 (0.48) | PTPN1CASP3KMT2AUSP2 | |
| SCHEMBL9449334 | 0.90 | PTPN1 (0.49) | PTPN1MDM4TP53CASP3KMT2A | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL120560 | 0.90 | MDM4 (0.58) | PTPN1MDM4TP53CASP3KMT2A | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL1002861 | 0.90 | MDM4 (0.58) | PTPN1MDM4TP53CASP3KMT2A | |
| N- (9-Fluorenylmethoxycarbonyl)-L-Leucine SCHEMBL800078 | 0.90 | MDM4 (0.58) | PTPN1MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | TTR, TTPA, SERPINA6 | PTPN1 2264/4885MDM4 3008/4885TP53 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.